Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of “Hold” from Brokerages

Share on StockTwits

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $26.57.

Several research firms recently issued reports on VNDA. Citigroup raised shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 2nd. Stifel Nicolaus reaffirmed a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, July 31st. Oppenheimer set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, May 5th. Finally, ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals stock traded up $0.28 during midday trading on Friday, hitting $15.19. 525,000 shares of the stock were exchanged, compared to its average volume of 915,671. Vanda Pharmaceuticals has a 1 year low of $11.83 and a 1 year high of $33.44. The firm has a market cap of $788.45 million, a P/E ratio of 31.65 and a beta of 0.38. The company has a 50 day moving average price of $13.91 and a two-hundred day moving average price of $16.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The firm had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. During the same quarter in the previous year, the firm posted $0.15 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts anticipate that Vanda Pharmaceuticals will post 0.32 EPS for the current fiscal year.

In other news, SVP Timothy Williams sold 2,575 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total value of $37,826.75. Following the completion of the sale, the senior vice president now owns 57,425 shares of the company’s stock, valued at approximately $843,573.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total transaction of $1,117,856.48. Following the completion of the sale, the chief executive officer now directly owns 1,276,343 shares of the company’s stock, valued at approximately $19,579,101.62. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Vanda Pharmaceuticals by 5.2% in the 2nd quarter. BlackRock Inc. now owns 8,987,677 shares of the biopharmaceutical company’s stock worth $126,636,000 after purchasing an additional 447,529 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Vanda Pharmaceuticals by 9.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,798,050 shares of the biopharmaceutical company’s stock worth $39,425,000 after purchasing an additional 233,300 shares during the last quarter. Invesco Ltd. increased its position in shares of Vanda Pharmaceuticals by 1.6% in the 2nd quarter. Invesco Ltd. now owns 1,521,183 shares of the biopharmaceutical company’s stock worth $21,434,000 after purchasing an additional 24,525 shares during the last quarter. Stonepine Capital Management LLC increased its position in shares of Vanda Pharmaceuticals by 6.5% in the 2nd quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock worth $18,908,000 after purchasing an additional 81,655 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $13,388,000. 99.33% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Story: What is the definition of market timing?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VANGUARD SCOTTS/VANGUARD RUSSELL 20  Shares Sold by Private Advisor Group LLC
VANGUARD SCOTTS/VANGUARD RUSSELL 20 Shares Sold by Private Advisor Group LLC
Private Advisor Group LLC Increases Stock Holdings in Invesco BulletShares 2019 Corporate Bond ETF
Private Advisor Group LLC Increases Stock Holdings in Invesco BulletShares 2019 Corporate Bond ETF
Private Advisor Group LLC Cuts Holdings in salesforce.com, inc.
Private Advisor Group LLC Cuts Holdings in salesforce.com, inc.
Private Advisor Group LLC Sells 25,360 Shares of PPL Corp
Private Advisor Group LLC Sells 25,360 Shares of PPL Corp
Invesco DWA Tactical Sector Rotation ETF  Shares Sold by Private Advisor Group LLC
Invesco DWA Tactical Sector Rotation ETF Shares Sold by Private Advisor Group LLC
PVG Asset Management Corp Sells 225,220 Shares of Ares Capital Co.
PVG Asset Management Corp Sells 225,220 Shares of Ares Capital Co.


 
© 2006-2019 Zolmax.